2,10-diazabicyclo<4.4.0>dec-1-ene | 60832-40-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,10-diazabicyclo<4.4.0>dec-1-ene
• 英文别名: 1,2,3,4,4a,5,6,7-octahydro-1,8-naphthyridine；(4aS)-1,2,3,4,4a,5,6,7-octahydro-1,8-naphthyridine
• CAS: 60832-40-8
• 化学式: C₈H₁₄N₂
• mdl: MFCD13176235
• 分子量: 138.213
• InChiKey: ZILBOLGGDPHJSW-UHFFFAOYSA-N

物化性质

• 熔点：
  113.0-114.5 °C
• 沸点：
  285.1±7.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,10-diazabicyclo<4.4.0>dec-1-ene 在 10-diazabicyclo<4.4.0>dec-1-ene.HBr 、 CBrCl₃₂ 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4a-Bromo-1,2,3,4,4a,5,6,7-octahydro-[1,8]naphthyridine
  参考文献：
  名称：

  Loefas, Stefan; Ahlberg, Per, journal of the chemical society-perkin transactions 2, 1986, p. 1223 - 1228

  摘要：

  DOI：
• 作为产物：
  描述：

  5-amino-2-(3-amino-propyl)-valeric acid 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 6.5h， 生成 2,10-diazabicyclo<4.4.0>dec-1-ene
  参考文献：
  名称：

  Loefas, Stefan; Ahlberg, Per, Journal of Heterocyclic Chemistry, 1984, vol. 21, p. 583 - 586

  摘要：

  DOI：
• 作为试剂：
  描述：

  1-phenyl-3-(2-tolyl)cyclohexene 在 2,10-diazabicyclo<4.4.0>dec-1-ene 作用下， 以 苯 为溶剂， 生成 3-phenyl-1-(2-tolyl)cyclohexene
  参考文献：
  名称：

  Ek, Marianne; Ahlberg, Per, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1984, vol. 38, # 3, p. 211 - 218

  摘要：

  DOI：

文献信息

• CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD

  公开号：US20200207782A1

  公开（公告）日：2020-07-02

  The present invention addresses the problem of providing a novel chemically activated water-soluble prodrug. The present invention provides a compound represented by formula (1), or a pharmacologically acceptable salt thereof (in the formula, A represents A-0; X 1 and X 2 are the same as or different from each other and each independently represent a hydroxyl group or —O—C(═O)—Y—(C(R 1A ) (R 1B ))n-NH—R 2 , where X 1 and X 2 are not simultaneously hydroxyl groups, n is 2, 3, or 4, Y represents an oxygen atom or —NR 4 , R 1A and R 1B are the same as or different from each other and each independently represent a hydrogen atom, etc., and R 2 represents a hydrogen atom, etc.; and R a to R d are optionally present, are the same as or different from each other, and each independently represent a hydrogen atom, etc.).

  本发明解决了提供一种新型化学活化的水溶性前药的问题。本发明提供了由式（1）表示的化合物，或其药理学上可接受的盐（在该式中，A代表A-0；X1和X2彼此相同或不同，每个独立地代表一个羟基或—O—C(═O)—Y—(C(R1A)(R1B))n-NH—R2，其中X1和X2不同时是羟基，n为2、3或4，Y代表氧原子或—NR4，R1A和R1B彼此相同或不同，每个独立地代表氢原子等，R2代表氢原子等；以及Ra到Rd可选地存在，彼此相同或不同，每个独立地代表氢原子等）。
• SMALL MOLECULES FOR ENDOTHELIAL CELL ACTIVATION
  申请人：The Regents of the University of California

  公开号：EP2963039A1

  公开（公告）日：2016-01-06

  The present invention provides small molecules for endothelial cell activation and compositions thereof and methods of making and using the same

  本发明提供了用于内皮细胞活化的小分子及其组合物，以及制备和使用这些小分子的方法。
• Boron−Boron Dehydrocoupling of Boranes Initiated by Reaction with Iodine
  作者：Jana Elias、Elisabeth Kaifer、Hans‐Jörg Himmel

  DOI：10.1002/chem.201900671

  日期：2019.5.7

  providing convenient access to some diborane(4) compounds starting from simple borane adducts under mild conditions. In contrast to the traditional pathway using a reducing reagent, the reduction from BIII to BII was paradoxically initiated by the addition of the oxidation‐reagent iodine. A reaction pathway for this unusual reaction was proposed based on quantum‐chemical calculations.

  建立了新的硼-硼脱氢偶联策略，可在温和条件下方便地从简单的硼烷加合物开始获取某些乙硼烷（4）化合物。与使用还原剂的传统途径相反，从B III到B II的还原是通过添加氧化试剂碘而自相矛盾地引发的。基于量子化学计算，提出了这种异常反应的反应途径。
• N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
  申请人：Targacept, Inc.

  公开号：US20040067930A1

  公开（公告）日：2004-04-08

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本文公开了N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物、以及这些化合物的前药或代谢物的制备和使用方法。芳基可以是五元或六元杂环（杂芳基）。这些化合物和组合物可用于治疗和/或预防各种疾病或障碍，特别是那些以尼古丁胆碱能神经递质功能障碍为特征的障碍，包括涉及神经递质释放的神经调节障碍，例如多巴胺释放。中枢神经系统障碍是另一个可以治疗和/或预防的例子，其特征是正常神经递质释放的改变。这些化合物和组合物也可用于缓解疼痛。这些化合物可以：（i）改变患者的大脑中尼古丁胆碱能受体的数量，（ii）表现出神经保护作用，以及（iii）在有效剂量下，不会导致明显的不良副作用（例如，明显增加血压和心率、对胃肠道的明显负面影响以及对骨骼肌的明显影响等副作用）。
• Use of N-aryl diazaspiracyclic compounds in the treatment of addiction
  申请人：Bhatti S. Balwinder

  公开号：US20060058328A1

  公开（公告）日：2006-03-16

  Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological “reward” process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, without resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

  本发明涉及用于治疗药物成瘾、尼古丁成瘾和/或肥胖症的化合物、组合物和方法。这些化合物是N-芳基二氮杂螺环化合物、N-杂芳基二氮杂螺环化合物的桥接类似物或这些化合物的前药或代谢物。芳基可以是五元或六元杂环环（杂芳基）。这些化合物能够有效地抑制多巴胺的产生和/或分泌，从而有效地抑制与尼古丁和/或非法药物摄入相关的生理“奖励”过程。这些化合物和组合物可以以有效剂量给予，以抑制多巴胺的释放，而不会导致明显的不良副作用（例如，显著增加血压和心率、对胃肠道产生显著负面影响以及对骨骼肌产生显著影响等副作用）。